Menu

CHA²DS²VASc

Riesgo tromboembólico y profilaxis antitrombótica en Fibrilación/Flutter Auricular (no valvular).
Calcular
Referencias:
  1. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
  2. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010;137:263–272.
Cerrar
Puntuación CHA²DS²VASc y Riesgo
Riesgo anual tromboembolico
Recomendación terapéutica
Riesgo de sangrado /anticoagulantes

**ACO: Dabigatran, Rivaroxaban, Apixaban
VKA: Antagonistas Vit.K

R.Pitarch ©© 2014